Credit: Pixabay/CC0 Public Domain
Ambroxol is a drug currently used to treat respiratory diseases. It promotes the elimination of mucus, relieves coughs and has anti-inflammatory properties.
A preclinical study led by Prof. Schapira at UCL Queen Square Neurology Institute identified ambroxol as a candidate drug to slow the progression of Parkinson’s disease.
Results from a Phase 2 clinical trial conducted by Professor Schapira at UCL were announced in January 2020, testing ambroxol in patients with Parkinson’s disease. It turns out that ambroxol can effectively reach the brain and increase levels of a protein known as GCase (glucocerebrosidase). GCase allows cells to remove waste proteins. α-Synuclein (a protein that accumulates in Parkinson’s disease and is thought to be important in its cause), making it more effective.
Additionally, a Phase 2 study showed that ambroxol is safe and well-tolerated in patients with Parkinson’s disease.
The world’s first Phase 3 trial, named ASPro-PD, is led by Professor Anthony Schapira in partnership with UK charities Cure Parkinson’s and the Van Andel Institute.
The trial will enroll 330 people with Parkinson’s disease at 10-12 clinical centers in the UK. A placebo-controlled participant will take ambroxol for her 2 years.
Ambroxol’s efficacy is measured by its ability to slow the progression of Parkinson’s disease using measures that include quality of life and movement. Preparations for recruitment of clinical trial participants have already begun.
“I am delighted to lead this exciting project,” said Professor Schapira. It represents extensive and in-depth research across: laboratory and clinical trial evidence of principle.
” research design is the result of valuable input from study design and statistics from Parkinson’s patients, a consortium of funders led by leaders in the Parkinson’s field, the UCL Comprehensive Clinical Trials Unit (CCTU), MHRA, and Cure Parkinson’s. Make sure your team reaches this stage.
“We look forward to working with all these groups to ensure the success of our research.”
After phase 2 data from UCL’s Professor Schapira’s group found that ambroxol could enhance the clearance of alpha-synuclein, the international Linked Clinical Trials (iLCT) program medicine.
Created and operated by Cure Parkinson’s and the Van Andel Institute, the iLCT program’s mission is to slow, stop and reverse the progression of Parkinson’s disease. Time to bringing disease-modifying therapies to the clinic for people with Parkinson’s disease by testing promising agents that already have extensive safety data and, in some cases, regulatory approval for other conditions It is intended to be significantly shortened.
Cure Parkinson’s CEO Will Cook said: A disease-modifying drug for Parkinson’s disease worldwide.
“Cure Parkinson’s is committed to significantly increasing this number over the next few years through our efforts within the iLCT program and through our fundraising efforts. cure for Parkinson’s. ”
provided by
University of London
Quote: Cough Medication Could Be a New Treatment for Parkinson’s Disease (11 Jan 2023) from https://medicalxpress.com/news/2023-01-medicine-treat-parkinson-disease.html Retrieved on 11 January 2023
This document is subject to copyright. No part may be reproduced without written permission, except in fair trade for personal research or research purposes. Content is provided for informational purposes only.
